VCYT

+ Watchlist + Portfolio

Veracyte, Inc.

Regulated industry Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $44.19
52-Week Range: $29.46 – $60.91
Market Cap: $3.68B
P/E (TTM): 32.72
EPS (TTM): 1.40
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.65
PEG Ratio: —
Return on Equity: 8.77%
Return on Assets: 4.09%
Gross Margin: 73.76%
Operating Margin: 15.29%
Profit Margin: 20.37%
Current Ratio: 9.16
Debt/Equity: 0.03
Total Debt: $40.11M
Free Cash Flow: $106.23M
Revenue Growth: 15.50%
Earnings Growth: —
Enterprise Value: $3.24B

VCYT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$296.54M	$361.05M	$445.76M	$517.14M
Cost of Revenue	$120.86M	$131.37M	$147.62M	$154.61M
Gross Profit	$175.68M	$229.68M	$298.14M	$362.53M
Research & Development	$40.60M	$57.30M	$69.29M	$70.81M
Selling, General & Admin	$170.76M	$187.72M	$206.04M	$210.95M
Operating Expenses	$211.02M	$247.13M	$278.63M	$284.25M
Operating Income	-$35.34M	-$17.45M	$19.51M	$78.28M
EBITDA	-$10.30M	-$49.41M	$49.20M	$89.62M
Pretax Income	-$36.43M	-$76.61M	$25.74M	$68.20M
Income Tax	$133.00K	-$2.21M	$1.61M	$1.85M
Net Income	-$36.56M	-$74.40M	$24.14M	$66.35M
Diluted EPS	-0.51	-1.02	0.31	0.82
Diluted Shares	71.55M	72.64M	78.16M	80.57M

VCYT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$154.25M	$216.45M	$239.09M	$362.58M
Receivables	$44.02M	$40.38M	$46.52M	$44.66M
Inventory	$14.29M	$16.13M	$21.75M	$20.55M
Current Assets	$248.64M	$285.62M	$372.27M	$488.38M
Total Assets	$1.16B	$1.11B	$1.30B	$1.41B
Current Liabilities	$62.61M	$61.24M	$78.63M	$59.94M
Total Debt	$14.72M	$12.63M	$50.74M	$39.65M
Total Liabilities	$81.22M	$70.80M	$124.07M	$96.44M
Retained Earnings	-$393.72M	-$468.12M	-$443.98M	-$377.63M
Shareholders' Equity	$1.08B	$1.04B	$1.18B	$1.31B
Working Capital	$186.02M	$224.38M	$293.63M	$428.44M

VCYT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$7.54M	$44.22M	$75.10M	$136.31M
Capital Expenditure	-$8.55M	-$9.96M	-$11.29M	-$9.68M
Free Cash Flow	-$1.01M	$34.26M	$63.81M	$126.63M
Depreciation & Amortisation	$25.93M	$27.19M	$23.46M	$21.41M
Stock-Based Compensation	$26.73M	$33.14M	$36.25M	$43.60M
Investing Cash Flow	-$29.39M	$15.11M	-$56.27M	-$9.21M
Financing Cash Flow	$3.49M	$2.84M	$4.90M	-$4.22M
Net Change in Cash	-$18.36M	$62.17M	$23.73M	$122.88M

VCYT Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$130.16M	$131.87M	$140.64M	$139.07M	$150.32M
Cost of Revenue	$40.40M	$40.59M	$38.66M	$37.91M	$41.77M
Gross Profit	$89.77M	$91.28M	$101.97M	$101.16M	$108.55M
Research & Development	$16.26M	$15.98M	$20.85M	$27.10M	$29.44M
Selling, General & Admin	$57.65M	$50.71M	$43.47M	$50.84M	$55.71M
Operating Expenses	$74.53M	$68.17M	$62.06M	$78.51M	$85.57M
Operating Income	$15.24M	$23.11M	$39.91M	$22.65M	$22.98M
EBITDA	$6.74M	$24.16M	$45.93M	$35.40M	$31.36M
Pretax Income	$1.25M	$18.89M	$40.63M	$29.97M	$26.52M
Income Tax	$2.23M	-$248.00K	-$515.00K	$1.27M	$1.03M
Net Income	-$980.00K	$19.14M	$41.15M	$28.71M	$25.49M
Diluted EPS	-0.01	0.24	0.51	0.35	0.31
Diluted Shares	78.39M	79.69M	81.39M	81.31M	82.06M

VCYT Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$219.50M	$315.57M	$362.58M	$263.14M	$299.52M
Receivables	$50.81M	$47.83M	$44.66M	$50.11M	$54.18M
Inventory	$25.02M	$20.33M	$20.55M	$21.42M	$22.66M
Current Assets	$414.68M	$449.22M	$488.38M	$522.17M	$574.77M
Total Assets	$1.34B	$1.37B	$1.41B	$1.44B	$1.49B
Current Liabilities	$76.43M	$72.15M	$59.94M	$56.12M	$62.74M
Total Debt	$50.65M	$40.45M	$39.65M	$39.33M	$40.11M
Total Liabilities	$123.05M	$110.12M	$96.44M	$91.99M	$97.96M
Retained Earnings	-$437.92M	-$418.78M	-$377.63M	-$348.92M	-$323.43M
Shareholders' Equity	$1.22B	$1.26B	$1.31B	$1.34B	$1.39B
Working Capital	$338.25M	$377.07M	$428.44M	$466.06M	$512.04M

VCYT Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$33.60M	$44.76M	$52.58M	$35.22M	$45.83M
Capital Expenditure	-$1.29M	-$2.79M	-$3.78M	-$2.96M	-$2.86M
Free Cash Flow	$32.32M	$41.97M	$48.80M	$32.25M	$42.97M
Depreciation & Amortisation	$5.49M	$5.27M	$5.30M	$5.43M	$4.84M
Stock-Based Compensation	$10.98M	$10.76M	$10.90M	$12.76M	$14.09M
Investing Cash Flow	-$224.00K	$48.26M	-$5.43M	-$127.96M	-$13.54M
Financing Cash Flow	-$566.00K	$2.98M	-$149.00K	-$6.63M	$4.14M
Net Change in Cash	$32.81M	$96.00M	$47.00M	-$99.38M	$36.42M

Market Snapshot

About

Veracyte is a genomic diagnostics company that develops and commercializes molecular tests for cancer diagnosis. The company provides solutions for thyroid, lung, prostate, breast, and bladder cancers, helping physicians make treatment decisions. Its products include Afirma, Prosigna, Percepta, Envisia, and Decipher tests.